Analyzing early successes, current challenges, and future opportunities in the in vivo cellular immunotherapy field

In vivo cellular immunotherapy has captured the imagination of many due to its obvious potential to alleviate the current supply chain cost and complexity issues associated with CAR-T cell therapy. David McCall, Senior Editor, BioInsights speaks to Ye Zeng, Postdoctoral Fellow, Bioengineering, Mitchell Lab, Department of Bioengineering, University of Pennsylvania, about the current state-of-the-art in this area of research, and the Mitchell Lab’s own work to develop non-viral delivery platforms with the capabilities to drive the field forward into a variety of therapeutic areas and disease indications.

Please enter your email to access content Read now